ATE326014T1 - Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma - Google Patents
Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasmaInfo
- Publication number
- ATE326014T1 ATE326014T1 AT99962732T AT99962732T ATE326014T1 AT E326014 T1 ATE326014 T1 AT E326014T1 AT 99962732 T AT99962732 T AT 99962732T AT 99962732 T AT99962732 T AT 99962732T AT E326014 T1 ATE326014 T1 AT E326014T1
- Authority
- AT
- Austria
- Prior art keywords
- ldl
- lipoprotein
- vldl
- compound
- plasma cholesterol
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 102000004895 Lipoproteins Human genes 0.000 abstract 4
- 108090001030 Lipoproteins Proteins 0.000 abstract 4
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000000853 LDL receptors Human genes 0.000 abstract 2
- 108010001831 LDL receptors Proteins 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- -1 e.g. Proteins 0.000 abstract 1
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10764498P | 1998-11-09 | 1998-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE326014T1 true ATE326014T1 (de) | 2006-06-15 |
Family
ID=22317677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99962732T ATE326014T1 (de) | 1998-11-09 | 1999-11-09 | Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1137948B1 (de) |
| JP (1) | JP2002529740A (de) |
| CN (1) | CN1332849A (de) |
| AT (1) | ATE326014T1 (de) |
| AU (1) | AU1911200A (de) |
| CA (1) | CA2350316A1 (de) |
| DE (1) | DE69931279T2 (de) |
| IL (2) | IL143057A0 (de) |
| MX (1) | MXPA01004683A (de) |
| WO (1) | WO2000028332A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670398B2 (en) | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
| CN1275596C (zh) * | 1997-05-14 | 2006-09-20 | 阿特罗吉尼克斯公司 | 普罗布考单酯在制备用于治疗心血管疾病和炎性疾病的药物中的应用 |
| US6852878B2 (en) | 1998-05-14 | 2005-02-08 | Atherogenics, Inc. | Thioketals and thioethers for inhibiting the expression of VCAM-1 |
| CO5170498A1 (es) * | 1999-05-28 | 2002-06-27 | Abbott Lab | Biaril sulfonamidas son utiles como inhibidores de proliferacion celular |
| US7012159B1 (en) | 1999-10-04 | 2006-03-14 | Nippon Soda Co., Ltd. | Phenolic compounds and recording materials containing the same |
| AU4765101A (en) * | 2000-03-21 | 2001-10-03 | Atherogenics Inc | Thioketals and thioethers for inhibiting the expression of vcam-1 |
| JP2003530383A (ja) | 2000-04-11 | 2003-10-14 | アセロジエニクス・インコーポレイテツド | 血漿ｈｄｌコレステロールレベルを上昇させ、ｈｄｌ機能性を向上させる化合物および方法 |
| AU2002308295B2 (en) | 2001-03-12 | 2007-08-23 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
| ITMI20020597A1 (it) * | 2002-03-22 | 2003-09-22 | Nicox Sa | Derivati del probucolo |
| WO2005102323A2 (en) | 2004-04-20 | 2005-11-03 | Atherogenics, Inc. | Process of preparing esters and ethers of probucol and derivatives thereof |
| BRPI0809423A2 (pt) | 2007-03-26 | 2014-09-09 | Salutria Pharmaceuticals Llc | Usos e composições de derivados de probucol para o tratamento de diabetes |
| US8048880B2 (en) | 2007-05-03 | 2011-11-01 | Anthera Pharmaceuticals, Inc. | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies |
| CA2765709A1 (en) * | 2009-06-17 | 2010-12-23 | Maine Standards Company, Llc | Method for measuring lipoprotein-specific apolipoproteins |
| CN108135973B (zh) * | 2015-05-19 | 2021-10-19 | 拉·约拉过敏反应及免疫医学研究所 | 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途 |
| WO2018045015A1 (en) * | 2016-09-01 | 2018-03-08 | Kevin Jon Williams | Methods and kits for reducing the susceptibility of lipoprotein particles to atherogenic aggregation induced by arterial-wall enzymes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
| US5155250A (en) * | 1990-07-05 | 1992-10-13 | Merrell Dow Pharmaceuticals Inc. | 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents |
| ATE324113T1 (de) * | 1993-12-10 | 2006-05-15 | Merrell Pharma Inc | Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom |
| US5608095A (en) * | 1996-04-30 | 1997-03-04 | Hoechst Marion Roussel, Inc. | Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents |
| CH691957A5 (de) * | 1996-09-03 | 2001-12-14 | Urs Tschudin | Schleifmaschine. |
-
1999
- 1999-11-09 EP EP99962732A patent/EP1137948B1/de not_active Expired - Lifetime
- 1999-11-09 MX MXPA01004683A patent/MXPA01004683A/es active IP Right Grant
- 1999-11-09 IL IL14305799A patent/IL143057A0/xx unknown
- 1999-11-09 AT AT99962732T patent/ATE326014T1/de not_active IP Right Cessation
- 1999-11-09 CN CN99815245A patent/CN1332849A/zh active Pending
- 1999-11-09 JP JP2000581459A patent/JP2002529740A/ja active Pending
- 1999-11-09 DE DE69931279T patent/DE69931279T2/de not_active Expired - Lifetime
- 1999-11-09 CA CA002350316A patent/CA2350316A1/en not_active Abandoned
- 1999-11-09 WO PCT/US1999/026519 patent/WO2000028332A1/en not_active Ceased
- 1999-11-09 AU AU19112/00A patent/AU1911200A/en not_active Abandoned
-
2001
- 2001-05-09 IL IL143057A patent/IL143057A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000028332A9 (en) | 2000-09-28 |
| AU1911200A (en) | 2000-05-29 |
| CN1332849A (zh) | 2002-01-23 |
| MXPA01004683A (es) | 2002-09-18 |
| WO2000028332A1 (en) | 2000-05-18 |
| CA2350316A1 (en) | 2000-05-18 |
| EP1137948A1 (de) | 2001-10-04 |
| IL143057A (en) | 2010-04-15 |
| DE69931279T2 (de) | 2007-04-12 |
| DE69931279D1 (de) | 2006-06-14 |
| IL143057A0 (en) | 2002-04-21 |
| EP1137948B1 (de) | 2006-05-10 |
| JP2002529740A (ja) | 2002-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE326014T1 (de) | Methode und zusammensetzungen zum vermindern des cholesterolspiegels im plasma | |
| Roberts et al. | A cell-based model of thrombin generation | |
| Barrans et al. | Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases | |
| Kane et al. | Prebeta-1 HDL and coronary heart disease | |
| Marais et al. | Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E | |
| ZA200107598B (en) | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein Al, very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol. | |
| MY121405A (en) | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines | |
| MY130670A (en) | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines | |
| MY121838A (en) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines | |
| Deakin et al. | HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity | |
| ATE204330T1 (de) | Verfahren zur bestimmung von cholesterin in high- density lipoproteinen | |
| ATE274068T1 (de) | Verfahren zur bestimmung von cholesterin in high- density-lipoprotein | |
| EP1392846A4 (de) | VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODIFIKATION DER BEARBEITUNG VON APOLIPOPROTEIN B-mRNA | |
| De Cristofaro et al. | The Asp272–Glu282 Region of Platelet Glycoprotein Ibα Interacts with the Heparin-binding Site of α-Thrombin and Protects the Enzyme from the Heparin-catalyzed Inhibition by Antithrombin III | |
| AU2864195A (en) | Class bi and ci scavenger receptors | |
| TW200510452A (en) | Compositions and methods for treating atherosclerosis | |
| WO2004005481A3 (en) | Methods for identifying modulators of mda-7 mediated apoptosis | |
| Connelly et al. | Kinetics of lipolysis of very low density lipoproteins by lipoprotein lipase. Importance of particle number and noncompetitive inhibition by particles with low triglyceride content. | |
| IL160533A0 (en) | Methods of screening molecules that are used to prevent cardiovascular diseases | |
| Daum et al. | Multiple dysfunctions of two apolipoprotein AI variants, apoA-I (R160L) Oslo and apoA-I (P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers | |
| Soutar et al. | The characterization of lipoproteins in the high density fraction obtained from patients with familial lecithin: cholesterol acyltransferase deficiency and their interaction with cultured human fibroblasts. | |
| Murthy et al. | Transglutaminase-catalyzed crosslinking of the Aα and γ constituent chains in fibrinogen | |
| Klein et al. | Phosphatidylethanolamine participates in the stimulation of the contact system of coagulation by very-low-density lipoproteins | |
| Kinoshita et al. | Scavenger receptor type BI potentiates reverse cholesterol transport system by removing cholesterol ester from HDL | |
| Minnich et al. | Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3'(Arg136–> His): association with mild dyslipidemia and double pre-beta very low density lipoproteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |